---
schema_version: "secwatch.filing_event.v1"
accession: "0001100682-25-000003"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T01:41:58.773220+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Charles River Labs provides preliminary 2025 outlook: revenue decline, CDMO client losses, potential impairment

## Summary
- Expects 2025 revenue to decline organically in similar range as estimated 2024; DSA demand consistent with H2 2024.
- CDMO revenue headwind: a cell therapy client terminated commercial agreement; lower revenue from another cell therapy client; ~1% consolidated revenue growth drag.
- Site consolidation actions (~0.5%) and FX (>1%) also expected to reduce reported revenue in 2025.
- Non-GAAP operating margin expected modestly below estimated 2024 level; cost savings cannot fully offset lower revenue.
- Assessing recoverability of goodwill and long-lived assets for potential impairment due to CDMO business challenges.

## SEC filing metadata
- accession: 0001100682-25-000003
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000110068225000003/0001100682-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000110068225000003/crl-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001100682-25-000003
- JSON: https://secwatch.observer/filing/0001100682-25-000003.json
- Plain text: https://secwatch.observer/filing/0001100682-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.